A Study of CAR-T Cells Targeting Autoimmune Diseases
- Sponsor
- Beijing Boren Hospital
- Study ID
- NCT06661811
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Autoimmune Diseases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- CAR-T — DRUGCAR-T cells
Study Details
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.
Key Dates
- First listed
- Oct 28, 2024
- Start date
- Nov 15, 2024
- Status verified
- Oct 2024
- Primary completion
- Apr 20, 2028
- Completion
- Jun 20, 2028
Study Design
- Enrollment
- 12 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CAR-T treatment
Primary Outcome Measure
Dose Limiting Toxicity [ Time Frame: 0~28 day after treatment ]
Central Contacts
- Yajing Zhang, MD/PhD+8601083605002(716)
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling By Invitation · Emory University · Atlanta, Georgia
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina
- Collection and Distribution of Biospecimens for Novel Research UsesRecruiting · iSpecimen Inc · Huntsville, Alabama